PMV Pharmaceuticals, Inc. - 8-K Filing
PMV Pharmaceuticals reported first-quarter financial results for 2026 with cash, cash equivalents, and marketable securities of $93.5 million as of March 31, 2026, providing an expected cash runway to the end of Q2 2027. The company recorded a net loss of $18 million for the quarter compared to $17.4 million in the same period last year, driven by lower R&D expenses and one-time benefits from prior NOL carryforward sales. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PMVP